twp 097i, holzschutzgrund -l- (m001000), as---m717, vb4000, marconol ultimate (preserver), k84 xilofil transparente, 677850 holzfreund active protection, s2368bc000.
troy chemical company bv, poortweg 4 c, 2612 pa, delft (nyderlandai) - propinilbutilkarbamatas, 3-jodo-2-propinilbutilkarbamatas, ipbc; propinilbutilkarbamatas, 3-jodo-2-propinilbutilkarbamatas, ipbc - veikliosios medžiagos cas nr.: 55406-53-6, eb nr.: 259-627-5, veikliosios medžiagos pavadinimas: propinilbutilkarbamatas, 3-jodo-2-propinilbutilkarbamatas, ipbc, koncentracija: 0.75% , veiklioji; veikliosios medžiagos cas nr.: 55406-53-6, eb nr.: 259-627-5, veikliosios medžiagos pavadinimas: propinilbutilkarbamatas, 3-jodo-2-propinilbutilkarbamatas, ipbc, koncentracija: 0.75% , veiklioji - medienos konservantai
galiron [licaformot]
septinta s.p.r.l. - formoterolio fumaratas - įkvepiamieji milteliai (kietosios kapsulės) - 12 µg - formoterol
multibic be kalio
fresenius medical care deutschland gmbh - natrio-vandenilio karbonatas/magnio chloridas heksahidratas/natrio chloridas/kalcio chloridas dihidratas/gliukozė - hemodializės ar hemofiltracijos tirpalas - 2,94 g/6,136 g/0,2237 g/0,2205 g/0,1017 g/1 g/1000 ml; 2,94 g/0,2205 g/0,1017 g/1 g/6,136 g/0,2982 g/1000 ml; 2,94 g/0,1017 g/6,136 g/0,2205 g/1 g/1000 ml; 2,94 g/6,136 g/0,1491 g/0,2205 g/0,1017 g/1 g/1000 ml; 2,94 g/6,136 g/0,2237 g/0,2 - hemofiltrates
medoclav
medochemie ltd. - amoksicilinas/klavulano rūgštis - milteliai geriamajai suspensijai - 400 mg/57 mg/5 ml - amoxicillin and beta-lactamase inhibitor
iohexol icg farma
icg farma, uab - joheksolis - injekcinis tirpalas - 647 mg/ml - iohexol
iohexol icg farma
icg farma, uab - joheksolis - injekcinis tirpalas - 755 mg/ml - iohexol
nulojix
bristol-myers squibb pharma eeig - belataceptas - graft rejection; kidney transplantation - imunosupresantai - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
tacforius
teva b.v. - takrolimuzo monohidratas - liver transplantation; kidney transplantation - imunosupresantai - profilaktiškai transplantacijos atmetimo suaugusiųjų inkstų arba kepenų allograft gavėjams. gydyti atmetimo, atsparūs gydymo imuninę sistemą slopinančiais vaistiniais preparatais suaugusių pacientų alotransplantato atmetimo reakciją.
thiotepa riemser
esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antinavikiniai vaistai - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.